Rescreening on RBANS Delayed Memory Index? Forget About It!

Author:

Sabbagh Marwan N.1,Michalak Wojciech2,Thim Hansen Charlotte3,Ahmad Wichmann Christian4,Clark Alice5

Affiliation:

1. Department of Neurology, Barrow Neurological Institute, Phoenix, AZ

2. Clinical Data Science & Evidence

3. Medical and Science

4. Medical Affairs

5. Real World Science - Obesity, Liver and CKAD, Novo Nordisk A/S, Søborg, Denmark

Abstract

Objective: To assess the value of rescreening patients with Alzheimer’s disease who do not meet the inclusion criteria for the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) at the initial assessment. Patients and Methods: Participants (aged 50–85 years, without dementia, Mini-Mental State Examination score ≥22, valid Clinical Dementia Rating [CDR] global score, and amyloid status at baseline) were identified in the European Prevention of Alzheimer’s Dementia database. Changes from baseline in RBANS DMI were estimated using a mixed model for repeated measurements. Logistic regressions were used to estimate the probability of participants with baseline RBANS DMI 86–95 having RBANS DMI ≤85, CDR global score ≥0.5, and amyloid positivity at 6 and 12 months. Results: There was significant variability in the change in RBANS DMI scores over time (median change at 6 months: 2.0). An estimated 15% of participants with RBANS DMI 86–95 at baseline progressed to ≤85 at 6 months; 8% also achieved CDR global score ≥0.5 and 5% were also amyloid positive. Conclusions: The results from our analysis indicate that there is limited value in rescreening patients based on their initial RBANS DMI score.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference16 articles.

1. Recommendations to address key recruitment challenges of Alzheimer’s disease clinical trials;Langbaum;Alzheimers Dement,2023

2. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity;Randolph;J Clin Exp Neuropsychol,1998

3. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): utility in detection and characterization of mild cognitive impairment due to Alzheimer’s disease;Karantzoulis;Arch Clin Neuropsychol,2013

4. Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to amyloid status in preclinical Alzheimer’s disease—atabecestat phase 2b/3 EARLY clinical trial;Papp;J Prev Alzheimers Dis,2022

5. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study;Novak;Alzheimers Res Ther,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3